Analysts expect Meridian Bioscience, Inc. (NASDAQ:VIVO) to report $0.20 EPS on April, 26 before the open.They anticipate $0.02 EPS change or 9.09% from last quarter’s $0.22 EPS. VIVO’s profit would be $8.46M giving it 18.38 P/E if the $0.20 EPS is correct. After having $0.15 EPS previously, Meridian Bioscience, Inc.’s analysts see 33.33% EPS growth. The stock increased 1.03% or $0.15 during the last trading session, reaching $14.7. About 132,014 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has risen 7.87% since April 17, 2017 and is uptrending. It has underperformed by 3.68% the S&P500.
Among 11 analysts covering Comstock Resources (NYSE:CRK), 2 have Buy rating, 3 Sell and 6 Hold. Therefore 18% are positive. Comstock Resources had 23 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Imperial Capital on Friday, February 26. The rating was maintained by Imperial Capital with “In-Line” on Friday, October 7. On Monday, August 14 the stock rating was maintained by Stifel Nicolaus with “Buy”. On Tuesday, January 19 the stock rating was downgraded by KLR Group to “Hold”. The firm has “Buy” rating given on Thursday, August 31 by Robert W. Baird. Robert W. Baird upgraded Comstock Resources, Inc. (NYSE:CRK) on Friday, January 27 to “Outperform” rating. As per Monday, October 16, the company rating was maintained by KeyBanc Capital Markets. The rating was maintained by RBC Capital Markets on Thursday, November 5 with “Sector Perform”. As per Monday, December 14, the company rating was downgraded by Howard Weil. The firm earned “Underperform” rating on Wednesday, July 22 by Credit Suisse. See Comstock Resources, Inc. (NYSE:CRK) latest ratings:
17/11/2017 Broker: Robert W. Baird Rating: Buy New Target: $12.0 Maintain
The stock decreased 7.47% or $0.39 during the last trading session, reaching $4.83. About 973,024 shares traded or 53.62% up from the average. Comstock Resources, Inc. (NYSE:CRK) has declined 12.00% since April 17, 2017 and is downtrending. It has underperformed by 23.55% the S&P500.
Comstock Resources, Inc., an independent energy company, acquires, develops, explores, and produces oil and natural gas properties in the United States. The company has market cap of $78.04 million. The Company’s gas and oil activities are primarily located in East Texas/North Louisiana and South Texas. It currently has negative earnings. The firm owns interests in 1,371 producing oil and natural gas wells.
Investors sentiment decreased to 1.2 in Q4 2017. Its down 0.17, from 1.37 in 2017Q3. It fall, as 21 investors sold Meridian Bioscience, Inc. shares while 44 reduced holdings. 31 funds opened positions while 47 raised stakes. 36.52 million shares or 0.72% more from 36.26 million shares in 2017Q3 were reported. Pennsylvania-based Connors Investor Services has invested 0.4% in Meridian Bioscience, Inc. (NASDAQ:VIVO). The Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). American Century holds 137,306 shares or 0% of its portfolio. Meeder Asset Inc has 0% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO). Parkside Finance Bancshares stated it has 43 shares. Tower Research Lc (Trc) reported 0.01% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Texas Permanent School Fund reported 28,528 shares. Citigroup Inc accumulated 75,750 shares. Glenmede Tru Na reported 0% stake. State Of Tennessee Treasury Department has invested 0% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO). Louisiana State Employees Retirement Sys, a Louisiana-based fund reported 18,200 shares. First Tru Advsrs Limited Partnership invested in 0% or 37,778 shares. California State Teachers Retirement System owns 65,661 shares for 0% of their portfolio. Morgan Stanley holds 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO) or 417,846 shares. Goldman Sachs Grp Inc Inc invested in 0% or 150,491 shares.
Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide. The company has market cap of $621.92 million. The firm operates through Diagnostics and Life Science divisions. It has a 28.82 P/E ratio. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.
Among 5 analysts covering Meridian Bioscience (NASDAQ:VIVO), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Meridian Bioscience had 13 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Piper Jaffray with “Sell” on Thursday, September 21. Hilliard Lyons upgraded the shares of VIVO in report on Monday, March 28 to “Buy” rating. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) has “Hold” rating given on Thursday, January 25 by Robert W. Baird. The firm has “Hold” rating by Robert W. Baird given on Thursday, October 19. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) earned “Sell” rating by Piper Jaffray on Thursday, July 27. Canaccord Genuity maintained the stock with “Hold” rating in Thursday, January 25 report. As per Thursday, January 25, the company rating was maintained by Piper Jaffray. The rating was downgraded by Hilliard Lyons on Monday, March 21 to “Neutral”. The firm earned “Sell” rating on Thursday, October 19 by Piper Jaffray. The firm has “Hold” rating by Canaccord Genuity given on Thursday, September 10.
Since February 7, 2018, it had 2 insider purchases, and 0 insider sales for $28,784 activity. McIlwraith John had bought 1,000 shares worth $14,034 on Friday, February 23. Shares for $14,750 were bought by Rice John McCune Jr. on Wednesday, February 7.